View Future GrowthCodexis 過去の業績過去 基準チェック /06Codexisの収益は年間平均-24.4%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.7% 11.7%割合で 減少しています。主要情報-24.38%収益成長率-19.37%EPS成長率Life Sciences 業界の成長36.86%収益成長率-11.71%株主資本利益率-87.03%ネット・マージン-62.47%次回の業績アップデート07 May 2026最近の業績更新Codexis, Inc. to Report Q1, 2026 Results on May 07, 2026Apr 23Full year 2025 earnings released: US$0.51 loss per share (vs US$0.89 loss in FY 2024) Mar 12Codexis, Inc. to Report Q4, 2025 Results on Mar 11, 2026Feb 25Codexis, Inc. to Report Q3, 2025 Results on Nov 06, 2025Oct 23Second quarter 2025 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2024) Aug 14Codexis, Inc. to Report Q2, 2025 Results on Aug 13, 2025Jul 31すべての更新を表示Recent updatesCodexis, Inc., Annual General Meeting, Jun 17, 2026Apr 30New minor risk - Profitability Apr 26No longer forecast to breakeven Apr 26Codexis, Inc. to Report Q1, 2026 Results on May 07, 2026Apr 23Full year 2025 earnings released: US$0.51 loss per share (vs US$0.89 loss in FY 2024) Mar 12Codexis, Inc. Provides Earnings Guidance for Full Year 2026Mar 12Codexis, Inc. to Report Q4, 2025 Results on Mar 11, 2026Feb 25New minor risk - Market cap size Feb 24Forecast to breakeven in 2028 Feb 06High number of new directors Feb 06Codexis, Inc. Announces Workforce ReductionNov 07+ 2 more updatesCodexis, Inc. to Report Q3, 2025 Results on Nov 06, 2025Oct 23Second quarter 2025 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2024) Aug 14Codexis, Inc. to Report Q2, 2025 Results on Aug 13, 2025Jul 31Codexis, Inc. Presents Data at the Tides USA Annual Meeting in San Diego, CaliforniaMay 22Codexis, Inc. Reiterates Earnings Guidance for Full-Year 2025May 15New major risk - Financial position May 15Codexis, Inc. to Report Q1, 2025 Results on May 14, 2025May 01Codexis, Inc., Annual General Meeting, Jun 10, 2025Apr 28Codexis, Inc. Announces Retirement of Byron L. Dorgan as DirectorApr 10Codexis, Inc. Appoints Cynthia Collins to the Board of DirectorsApr 01New minor risk - Profitability Mar 08Forecast to breakeven in 2027 Mar 07New minor risk - Profitability Mar 03 Feb 28Now 29% undervalued after recent price drop Feb 28Codexis, Inc. Provides Earnings Guidance for 2025Feb 28Full year 2024 earnings released: US$0.89 loss per share (vs US$1.12 loss in FY 2023) Feb 28Codexis, Inc. to Report Q4, 2024 Results on Feb 27, 2025Feb 14Codexis, Inc. Appoints Arthur Levin to Strategic Advisory BoardFeb 09Now 23% undervalued Jan 23Codexis, Inc. Appoints Christos Richards to Board of DirectorsJan 17Now 21% undervalued Jan 08New major risk - Share price stability Dec 10Codexis, Inc. Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi TherapeuticsNov 15Codexis, Inc. Appoints Raymond De Vré to Board of DirectorsNov 13New minor risk - Shareholder dilution Nov 05Third quarter 2024 earnings released: US$0.29 loss per share (vs US$0.50 loss in 3Q 2023) Nov 01Codexis, Inc. to Report Q3, 2024 Results on Oct 31, 2024Oct 11Codexis, Inc. Announces Executive ChangesOct 03Second quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 2Q 2023) Aug 09Codexis, Inc. Reiterates Earnings Guidance for the Full Year 2024Aug 09Codexis, Inc. to Report Q2, 2024 Results on Aug 08, 2024Jul 19Codexis, Inc. (NasdaqGS:CDXS) entered into an asset purchase agreement to acquire Gene Therapy Assets of Crosswalk Therapeutics.Jul 02Codexis, Inc. Presents Enzymatic Synthesis Data at TIDES USA Annual Meeting and Launches RNA Ligase Screening and Optimization ServicesMay 15First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.34 loss in 1Q 2023) May 03Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024May 03Codexis, Inc., Annual General Meeting, Jun 11, 2024Apr 28Codexis, Inc. to Report Q1, 2024 Results on May 02, 2024Apr 20Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory BoardApr 11High number of new directors Mar 01Full year 2023 earnings released: US$1.12 loss per share (vs US$0.51 loss in FY 2022) Feb 29New major risk - Revenue and earnings growth Feb 29Codexis, Inc Appoints Masad Damha, PhD and Jim Lalonde, PhD to Strategic Advisory BoardFeb 21Codexis, Inc. Announces Not to Stand for Reelection of Jennifer Aaker as Board of DirectorFeb 17Codexis, Inc. to Report Q4, 2023 Results on Feb 28, 2024Feb 15+ 1 more updateseqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General MeetingFeb 02Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS).Dec 14Codexis, Inc. Reiterates Earnings Guidance for the Year 2023Nov 03Third quarter 2023 earnings released: US$0.50 loss per share (vs US$0.15 loss in 3Q 2022) Nov 03Codexis, Inc. to Present Update on Eco Synthesis Platform At Tides EuropeOct 28Codexis, Inc. to Report Q3, 2023 Results on Nov 02, 2023Oct 20Codexis, Inc. to Report Q2, 2023 Results on Aug 03, 2023Jul 23+ 2 more updatesNow 23% undervalued after recent price drop Jun 01Codexis, Inc. Unveils Eco Synthesis Platform for Large-Scale RNAi Therapeutics Production at Tides USAMay 11Codexis, Inc. Provides Revenue Guidance for the Year 2023May 06First quarter 2023 earnings released: US$0.34 loss per share (vs US$0.13 loss in 1Q 2022) May 05Chief Operating Officer recently sold US$77k worth of stock Mar 12Full year 2022 earnings released: US$0.51 loss per share (vs US$0.33 loss in FY 2021) Feb 24Codexis, Inc. to Report Q4, 2022 Results on Feb 23, 2023Feb 10Codexis, Inc. Announces Cessation of Ross Taylor as Principal Financial and Accounting OfficerFeb 04+ 1 more updateCodexis, Inc. Announces Appointment of Sri Ryali as Chief Financial OfficerJan 24High number of new directors Nov 16Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.035 profit in 3Q 2021) Nov 05High number of new directors Nov 02Second quarter 2022 earnings released: US$0.04 loss per share (vs US$0.066 loss in 2Q 2021) Aug 05Now 39% undervalued after recent price drop Jul 15First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 1Q 2021) May 07Now 21% undervalued after recent price drop Apr 28No longer forecast to breakeven Apr 27No longer forecast to breakeven Mar 17Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26Forecast to breakeven in 2024 Jan 13Third quarter 2021 earnings released: EPS US$0.035 (vs US$0.10 loss in 3Q 2020) Nov 06Second quarter 2021 earnings released: US$0.066 loss per share (vs US$0.11 loss in 2Q 2020) Aug 08High number of new directors Aug 06収支内訳Codexis の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史LSE:0I0X 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2570-4447030 Sep 2553-6449030 Jun 2557-6551031 Mar 2550-7455031 Dec 2459-6555030 Sep 2464-6254030 Jun 2461-7653031 Mar 2474-6551031 Dec 2370-7653030 Sep 2374-8253030 Jun 2399-5755031 Mar 23116-4852031 Dec 22139-3452030 Sep 22133-3152030 Jun 22135-1951031 Mar 22122-2154031 Dec 21105-2149030 Sep 21101-1546030 Jun 2183-2342031 Mar 2172-2537031 Dec 2069-2435030 Sep 2067-2134030 Jun 2070-1433031 Mar 2068-1432031 Dec 1968-1232030 Sep 1966-1231030 Jun 1961-1430031 Mar 1962-1130031 Dec 1861-1129030 Sep 1866-930030 Jun 1859-1831031 Mar 1856-2030031 Dec 1750-2329030 Sep 1738-2928030 Jun 1743-1825031 Mar 1749-925031 Dec 1649-925030 Sep 1650-524030 Jun 1653-125031 Mar 1643-924031 Dec 1542-822030 Sep 1544-521030 Jun 1534-15210質の高い収益: 0I0Xは現在利益が出ていません。利益率の向上: 0I0Xは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 0I0Xは利益が出ておらず、過去 5 年間で損失は年間24.4%の割合で増加しています。成長の加速: 0I0Xの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 0I0Xは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 13.9% ) と比較することは困難です。株主資本利益率高いROE: 0I0Xは現在利益が出ていないため、自己資本利益率 ( -87.03% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 16:08終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Codexis, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関J. HorwitzBairdVishal ShahBarclaysRobert WassermanBenchmark Company15 その他のアナリストを表示
Codexis, Inc. Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi TherapeuticsNov 15
Codexis, Inc. (NasdaqGS:CDXS) entered into an asset purchase agreement to acquire Gene Therapy Assets of Crosswalk Therapeutics.Jul 02
Codexis, Inc. Presents Enzymatic Synthesis Data at TIDES USA Annual Meeting and Launches RNA Ligase Screening and Optimization ServicesMay 15
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General MeetingFeb 02
Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS).Dec 14
Codexis, Inc. Unveils Eco Synthesis Platform for Large-Scale RNAi Therapeutics Production at Tides USAMay 11
Codexis, Inc. Announces Cessation of Ross Taylor as Principal Financial and Accounting OfficerFeb 04+ 1 more update